DISHMAN PHARMA | DR. DATSONS LABS | DISHMAN PHARMA/ DR. DATSONS LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 25.1 | -10.9 | - | View Chart |
P/BV | x | 3.3 | 0.2 | 2,061.5% | View Chart |
Dividend Yield | % | 0.7 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
DR. DATSONS LABS Mar-14 |
DISHMAN PHARMA/ DR. DATSONS LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 126 | 298.1% | |
Low | Rs | 129 | 31 | 417.2% | |
Sales per share (Unadj.) | Rs | 197.8 | 133.0 | 148.7% | |
Earnings per share (Unadj.) | Rs | 21.2 | 0.2 | 13,987.0% | |
Cash flow per share (Unadj.) | Rs | 34.7 | 6.6 | 525.5% | |
Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
Dividend yield (eoy) | % | 0.8 | 0 | - | |
Book value per share (Unadj.) | Rs | 179.9 | 128.8 | 139.7% | |
Shares outstanding (eoy) | m | 80.69 | 31.66 | 254.9% | |
Bonus/Rights/Conversions | - | FCCB | - | ||
Price / Sales ratio | x | 1.3 | 0.6 | 216.2% | |
Avg P/E ratio | x | 11.9 | 516.1 | 2.3% | |
P/CF ratio (eoy) | x | 7.2 | 11.8 | 61.2% | |
Price / Book Value ratio | x | 1.4 | 0.6 | 230.2% | |
Dividend payout | % | 9.4 | 0 | - | |
Avg Mkt Cap | Rs m | 20,306 | 2,477 | 819.6% | |
No. of employees | `000 | 0.8 | NA | - | |
Total wages/salary | Rs m | 5,355 | 56 | 9,562.3% | |
Avg. sales/employee | Rs Th | 19,252.7 | NM | - | |
Avg. wages/employee | Rs Th | 6,459.5 | NM | - | |
Avg. net profit/employee | Rs Th | 2,064.1 | NM | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,961 | 4,211 | 379.1% | |
Other income | Rs m | 265 | 79 | 337.2% | |
Total revenues | Rs m | 16,226 | 4,289 | 378.3% | |
Gross profit | Rs m | 4,103 | 569 | 721.6% | |
Depreciation | Rs m | 1,091 | 204 | 533.6% | |
Interest | Rs m | 944 | 430 | 219.5% | |
Profit before tax | Rs m | 2,334 | 13 | 18,374.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1 | -2 | -61.1% | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 624 | 6 | 10,223.0% | |
Profit after tax | Rs m | 1,711 | 5 | 35,647.9% | |
Gross profit margin | % | 25.7 | 13.5 | 190.4% | |
Effective tax rate | % | 26.7 | 48.0 | 55.6% | |
Net profit margin | % | 10.7 | 0.1 | 9,404.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 6,852 | 160.8% | |
Current liabilities | Rs m | 9,517 | 6,711 | 141.8% | |
Net working cap to sales | % | 9.4 | 3.3 | 280.8% | |
Current ratio | x | 1.2 | 1.0 | 113.4% | |
Inventory Days | Days | 110 | 161 | 68.7% | |
Debtors Days | Days | 35 | 318 | 10.9% | |
Net fixed assets | Rs m | 16,304 | 3,673 | 443.9% | |
Share capital | Rs m | 161 | 317 | 51.0% | |
"Free" reserves | Rs m | 12,907 | 3,761 | 343.2% | |
Net worth | Rs m | 14,516 | 4,078 | 356.0% | |
Long term debt | Rs m | 4,189 | 1,671 | 250.7% | |
Total assets | Rs m | 29,805 | 12,633 | 235.9% | |
Interest coverage | x | 3.5 | 1.0 | 337.1% | |
Debt to equity ratio | x | 0.3 | 0.4 | 70.4% | |
Sales to assets ratio | x | 0.5 | 0.3 | 160.7% | |
Return on assets | % | 8.9 | 3.4 | 258.7% | |
Return on equity | % | 11.8 | 0.1 | 10,013.7% | |
Return on capital | % | 17.5 | 7.7 | 228.5% | |
Exports to sales | % | 24.8 | 22.9 | 108.3% | |
Imports to sales | % | 3.7 | 14.3 | 26.1% | |
Exports (fob) | Rs m | 3,956 | 964 | 410.4% | |
Imports (cif) | Rs m | 596 | 602 | 99.1% | |
Fx inflow | Rs m | 4,952 | 964 | 513.6% | |
Fx outflow | Rs m | 697 | 607 | 114.8% | |
Net fx | Rs m | 4,255 | 357 | 1,192.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | 1,345 | 207.2% | |
From Investments | Rs m | -1,529 | -2,256 | 67.8% | |
From Financial Activity | Rs m | -941 | -1,200 | 78.4% | |
Net Cashflow | Rs m | 316 | -2,111 | -15.0% |
Indian Promoters | % | 61.4 | 4.5 | 1,355.4% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 3.7 | 0.0 | - | |
FIIs | % | 12.7 | 1.4 | 940.7% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 22.1 | 94.1 | 23.5% | |
Shareholders | 46,261 | 20,807 | 222.3% | ||
Pledged promoter(s) holding | % | 35.8 | 0.0 | - |
Compare DISHMAN PHARMA With: ELDER PHARMA FDC SUN PHARMA FRESENIUS KABI ONCO. TTK HEALTHCARE
Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed heavy selling pressure today despite the US administration saying it would bring a stimulus package even without the opposition's support.
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More